Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.



Research Clients



Reports published



Readers in database

Post hoc #FALUCA analysis presented at #WCLC19 suggests use of subsequent therapy contributed to the OS primary endpoint miss in #NSCLC. However, #Fruquintinib's key near-term catalyst is potential NRDL inclusion in Q419 $HCM
Read our note at

Potential new opportunity for #Angle: @QMBCI study demonstrates @Parsortix #liquidbiopsy utility in early-stage #prostate cancer detection, with potential to decrease unnecessary biopsies published in @JUrology $AGL.L

.@MereoBioPharma will be presenting the 6-month data from the open label arm of the ongoing Phase ASTEROID IIb study with setrusumab (BPS-804) in osteogenesis imperfecta (brittle bone disease) at #ASBMR meeting. https://t.co/9mVvkQYZpi

.@scancellpharma has formed a non-exclusive collaboration with a leading antibody technology company, with a view to out-licensing its glycan antibodies and AvidiMab technology to fund ImmunoBody and Moditope development. Read our note at https://t.co/mZuSJRY5Vy

A verification study run by @WilmotCancer to confirm the utility of ANGLE PLC's @Parsortix and Ziplex platforms to identify which women with abnormal pelvic masses have #ovariancancer has been initiated https://t.co/TkijzIOsIV

Read our Update note on @scancellpharma at https://t.co/mZuSJRY5Vy, following the start of the Phase II study with ImmunoBody SCIB1 in combination with Keytruda in #melanoma and publication of its FY19 results.

Subscribe to our research

Please sign up here to be added to our distribution database